Haploidentical NK Cell Infusion in Malignant Melanoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
We hypothesized that haploidentical NK cells kill tumor cells more efficiently than autologous NK cells, based on the missing-self hypothesis. Therefore, we performed this study to investigate the role of haploidentical NK cell therapy in patients with refractory or relapsed malignant melanoma.
Condition or disease
Biological: Haploidentical NK cell
Phase 1Phase 2
Human NK cells recognize and kill transformed cells in a MHC-unrestricted fashion, suggesting the role of cancer immunotherapy. However, autologous NK cells showed the lack of significant clinical effects, because they are inhibited by self MHC class I molecules, based on the missing-self hypothesis. Contrarily, haploidentical NK cells with KIR-ligand incompatibility can mediate graft-versus-leukemia effect and protect patients with acute myelogenous leukemia (AML) from graft-versus-host disease. In addition, adoptive transfer of haploidentical NK cells following high-intensity conditioning induced complete remission (26%) in poor-prognosis AML patients. Thus, this study was designed to investigate the role of adoptive NK cell therapy in patients with refractory or relapsed malignant melanoma using CD3+ depleting CliniMACS® system.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically confirmed metastatic or relapsed malignant melanoma
Patients who received prior chemotherapy or immunotherapy
Patients who have at least one haploidentical donor willing to donate
ECOG performance status 0 or 1
18 - 75 years
At least one measurable disease according to the RECIST criteria
Patients with 45% or more left ventricular ejection fraction
Patients with 50% or more predicted DLCO
Adequate bone marrow function: absolute neutrophil count ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L; and hemoglobin ≥ 9 g/dL
Adequate liver function: total bilirubin ≤ 1.0 x upper limit of the normal range (ULN); AST/ALT ≤ 2.5 x ULN; and alkaline phosphatase ≤ 2.5 x ULN
Adequate renal function: serum creatinine ≤ 1.0 x ULN or creatinine clearance ≥ 60 mL/min/1.73m2
At least 3 months of expected survival
Patients who signed informed consent
Patients who received other chemotherapeutic agents within 30 days prior to study enrollment
Patients who received adoptive cell therapy including hematopoietic stem cell transplantation
Patients infected with HIV, HBV, or HCV
Hypersensitivity to cyclophosphamide or interleukin-2
Patients who received organ transplantation
Patients who had arrhythmia or ischemic heart disease
Pregnant or lactating women
Patients with uncontrolled infection who did not respond to appropriate antimicrobial agents